NASDAQ:SRDX Surmodics (SRDX) Stock Forecast, Price & News $17.67 -0.06 (-0.34%) (As of 05/26/2023 04:00 PM ET) Add Compare Share Share Today's Range$17.43▼$17.8350-Day Range$17.13▼$24.2352-Week Range$16.00▼$40.21Volume62,800 shsAverage Volume147,071 shsMarket Capitalization$249.68 millionP/E RatioN/ADividend YieldN/APrice Target$47.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Surmodics MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside166.0% Upside$47.00 Price TargetShort InterestHealthy1.84% of Float Sold ShortDividend StrengthN/ASustainability-2.52Upright™ Environmental ScoreNews Sentiment0.63Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.85) to ($1.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.36 out of 5 starsMedical Sector265th out of 1,010 stocksSurgical & Medical Instruments Industry26th out of 104 stocks 3.3 Analyst's Opinion Consensus RatingSurmodics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $47.00, Surmodics has a forecasted upside of 166.0% from its current price of $17.67.Amount of Analyst CoverageSurmodics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.84% of the float of Surmodics has been sold short.Short Interest Ratio / Days to CoverSurmodics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Surmodics has recently decreased by 6.87%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSurmodics does not currently pay a dividend.Dividend GrowthSurmodics does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSurmodics has received a 38.03% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Synthetic antigens", " Coatings for drug delivery devices", and "Medical equipment engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Surmodics is -2.52. Previous Next 2.6 News and Social Media Coverage News SentimentSurmodics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Surmodics this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Surmodics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Surmodics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.50% of the stock of Surmodics is held by insiders.Percentage Held by Institutions96.49% of the stock of Surmodics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Surmodics are expected to grow in the coming year, from ($1.85) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Surmodics is -6.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Surmodics is -6.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSurmodics has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Surmodics (NASDAQ:SRDX) StockSurmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.Read More Receive SRDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter. Email Address SRDX Stock News HeadlinesMay 25, 2023 | finance.yahoo.comSurmodics to Participate in the Jefferies Healthcare Conference on June 8May 22, 2023 | americanbankingnews.comSurmodics (NASDAQ:SRDX) Now Covered by StockNews.comMay 30, 2023 | Edge On The Street (Ad)The Largest Ever Technology Wave Is Coming!This summer, a small tech company will launch a key technology to advance artificial intelligence, or AI, that can think, reason and make decisions like humans. It will change the world, just like electricity did.May 16, 2023 | finance.yahoo.comHere's Why SurModics (SRDX) Is a Great 'Buy the Bottom' Stock NowMay 15, 2023 | finance.yahoo.comDown -18.32% in 4 Weeks, Here's Why You Should You Buy the Dip in SurModics (SRDX)May 14, 2023 | finance.yahoo.comIn the wake of Surmodics, Inc.'s (NASDAQ:SRDX) latest US$31m market cap drop, institutional owners may be forced to take severe actionsMay 14, 2023 | americanbankingnews.comSurmodics, Inc. (NASDAQ:SRDX) Sees Large Decline in Short InterestMay 12, 2023 | msn.comSurmodics files for $200M mixed shelf offeringMay 30, 2023 | Edge On The Street (Ad)How to Invest in AI's Fast-Growing MarketThe AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.May 3, 2023 | finance.yahoo.comSurmodics, Inc. (NASDAQ:SRDX) Q2 2023 Earnings Call TranscriptMay 2, 2023 | americanbankingnews.comQ3 2023 Earnings Forecast for Surmodics, Inc. (NASDAQ:SRDX) Issued By Barrington ResearchApril 30, 2023 | msn.comSurmodics's Return on Invested Capital InsightsApril 30, 2023 | marketwatch.comWhen the Price of Surmodics $SRDX Talks, People ListenApril 27, 2023 | finance.yahoo.comSurmodics (SRDX) Q2 Earnings Top Estimates, FY23 View RevisedApril 25, 2023 | americanbankingnews.comSurmodics (SRDX) Scheduled to Post Earnings on WednesdayApril 17, 2023 | finance.yahoo.comSurmodics, Inc. (NASDAQ:SRDX) Stocks Shoot Up 36% But Its P/S Still Looks ReasonableApril 10, 2023 | finance.yahoo.comInvestors in Surmodics (NASDAQ:SRDX) have unfortunately lost 44% over the last yearMarch 29, 2023 | finance.yahoo.comSurmodics (SRDX) Gets FDA's Formal Feedback About SurVeil DCBMarch 28, 2023 | finance.yahoo.comSurmodics Provides Regulatory Update on its Strategy to Submit an Amended Premarket Approval Application for the SurVeil™ Drug-Coated BalloonMarch 18, 2023 | benzinga.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDXMarch 17, 2023 | finance.yahoo.comSurModics (SRDX) Moves 5.4% Higher: Will This Strength Last?March 8, 2023 | finance.yahoo.comSurModics (SRDX) Down 37.2% Since Last Earnings Report: Can It Rebound?February 25, 2023 | benzinga.comROSEN, National Trial Lawyers, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDXFebruary 17, 2023 | benzinga.comROSEN, Global Investor Counsel, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDXFebruary 9, 2023 | benzinga.comNATIONALLY RANKED ROSEN LAW FIRM Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDXFebruary 9, 2023 | insidermonkey.comSurmodics, Inc. (NASDAQ:SRDX) Q1 2023 Earnings Call TranscriptFebruary 8, 2023 | msn.comSurmodics's Return On Capital Employed InsightsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SRDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter. Email Address SRDX Company Calendar Last Earnings2/06/2023Today5/30/2023Next Earnings (Estimated)7/26/2023Fiscal Year End9/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:SRDX CUSIP86887310 CIK924717 Webwww.surmodics.com Phone(952) 500-7000Fax952-500-7001Employees389Year Founded1979Price Target and Rating Average Stock Price Forecast$47.00 High Stock Price Forecast$60.00 Low Stock Price Forecast$34.00 Forecasted Upside/Downside+166.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,270,000.00 Net Margins-34.92% Pretax Margin-28.50% Return on Equity-18.98% Return on Assets-12.56% Debt Debt-to-Equity Ratio0.29 Current Ratio3.20 Quick Ratio2.48 Sales & Book Value Annual Sales$99.95 million Price / Sales2.50 Cash FlowN/A Price / Cash FlowN/A Book Value$7.75 per share Price / Book2.28Miscellaneous Outstanding Shares14,130,000Free Float13,073,000Market Cap$249.68 million OptionableOptionable Beta1.02 Social Links Key ExecutivesGary R. MaharajPresident, Chief Executive Officer & DirectorTimothy J. ArensCFO, SVP-Finance & Information TechnologyCharles W. OlsonPresident-Medical Device Coatings & SVPTeri L. W. SidesPresident-Vascular Interventions & SVPJohn D. MandersVice President-Finance & ControllerKey CompetitorsAccurayNASDAQ:ARAYAngioDynamicsNASDAQ:ANGOOrthofix MedicalNASDAQ:OFIXCardiovascular SystemsNASDAQ:CSIIAlpha Tau MedicalNASDAQ:DRTSView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Sold 52,404 shares on 5/22/2023Ownership: 0.299%JPMorgan Chase & Co.Bought 1,510 shares on 5/18/2023Ownership: 0.104%New York State Common Retirement FundSold 5,200 shares on 5/18/2023Ownership: 0.040%Segall Bryant & Hamill LLCSold 3,724 shares on 5/16/2023Ownership: 2.306%RBF Capital LLCSold 2,232 shares on 5/16/2023Ownership: 0.071%View All Insider TransactionsView All Institutional Transactions SRDX Stock - Frequently Asked Questions Should I buy or sell Surmodics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surmodics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SRDX shares. View SRDX analyst ratings or view top-rated stocks. What is Surmodics' stock price forecast for 2023? 2 Wall Street research analysts have issued twelve-month target prices for Surmodics' stock. Their SRDX share price forecasts range from $34.00 to $60.00. On average, they anticipate the company's share price to reach $47.00 in the next twelve months. This suggests a possible upside of 166.0% from the stock's current price. View analysts price targets for SRDX or view top-rated stocks among Wall Street analysts. How have SRDX shares performed in 2023? Surmodics' stock was trading at $34.12 at the start of the year. Since then, SRDX shares have decreased by 48.2% and is now trading at $17.67. View the best growth stocks for 2023 here. When is Surmodics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023. View our SRDX earnings forecast. How were Surmodics' earnings last quarter? Surmodics, Inc. (NASDAQ:SRDX) issued its quarterly earnings data on Monday, February, 6th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.63) by $0.13. The firm earned $24.93 million during the quarter, compared to analyst estimates of $24.19 million. Surmodics had a negative net margin of 34.92% and a negative trailing twelve-month return on equity of 18.98%. During the same period in the prior year, the firm posted ($0.13) earnings per share. What ETFs hold Surmodics' stock? ETFs with the largest weight of Surmodics (NASDAQ:SRDX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), SPDR S&P Health Care Equipment ETF (XHE).iShares U.S. Medical Devices ETF (IHI) and What guidance has Surmodics issued on next quarter's earnings? Surmodics updated its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of -$1.98--$1.68 for the period, compared to the consensus estimate of -$1.90. The company issued revenue guidance of $103.00 million-$106.00 million, compared to the consensus revenue estimate of $104.34 million. What is Gary Maharaj's approval rating as Surmodics' CEO? 8 employees have rated Surmodics Chief Executive Officer Gary Maharaj on Glassdoor.com. Gary Maharaj has an approval rating of 65% among the company's employees. What other stocks do shareholders of Surmodics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Surmodics investors own include Gilead Sciences (GILD), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), NVIDIA (NVDA), Tandem Diabetes Care (TNDM), uniQure (QURE), Sangamo Therapeutics (SGMO), Abbott Laboratories (ABT) and Dynavax Technologies (DVAX). What is Surmodics' stock symbol? Surmodics trades on the NASDAQ under the ticker symbol "SRDX." Who are Surmodics' major shareholders? Surmodics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Trigran Investments Inc. (16.69%), BlackRock Inc. (7.18%), Renaissance Technologies LLC (4.48%), Dimensional Fund Advisors LP (3.00%), State Street Corp (2.55%) and Segall Bryant & Hamill LLC (2.31%). Insiders that own company stock include Charles W Olson, Charles W Olson, David Dantzker, Gary R Maharaj, Gary R Maharaj, John D Manders, Jose H Bedoya, Jose H Bedoya, Joseph J Stich, Joseph J Stich and Ronald B Sr Kalich Sr. View institutional ownership trends. How do I buy shares of Surmodics? Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Surmodics' stock price today? One share of SRDX stock can currently be purchased for approximately $17.67. How much money does Surmodics make? Surmodics (NASDAQ:SRDX) has a market capitalization of $249.68 million and generates $99.95 million in revenue each year. The company earns $-27,270,000.00 in net income (profit) each year or ($2.58) on an earnings per share basis. How many employees does Surmodics have? The company employs 389 workers across the globe. How can I contact Surmodics? Surmodics' mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The official website for the company is www.surmodics.com. The company can be reached via phone at (952) 500-7000, via email at ir@surmodics.com, or via fax at 952-500-7001. This page (NASDAQ:SRDX) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surmodics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.